


The Regenexx Approach vs. Elective Orthopedic Surgery: A Claims-Based Outcomes Study

Commercial Claims Data · 2016 – 2023 · Propensity-Matched Cohort Analysis · Duke University / DCRI


“The Regenexx approach provides a high-value, cost-savings alternative to elective orthopedic surgeries.”
— Duke University / DCRI Conclusion · Lentz et al., 2026

In 2026, Duke University and the Duke Clinical Research Institute published an IRB-approved study comparing the Regenexx approach against four elective orthopedic surgeries. The research team analyzed seven years of commercial claims data using propensity-matched methodology.

PER-PATIENT SAVINGS & RE-OPERATION RATES — THE REGENEXX APPROACH VS. SURGERY



CLINICAL & UTILIZATION OUTCOMES — REGENEXX APPROACH VS. TKA



Lentz et al. (2026) · Duke University / DCRI · Commercial Claims Data · 2016–2023 · IRB Approved
Procedures using Regenexx injectates have a success and failure rate. Individual results will vary.

Mark A. Testa, DC, MHA · Regenexx Corporate
mtesta@regenexx.com · regenexxcorporate.com
calendly.com/mark_testa/30min